tbuckley/cabot-search huggingface dataset:
Hypothermia After Traumatic Brain Injury
Authors: Annemarie Docherty, John Emelifeonwu, Peter J. D. Andrews
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
Authors: A. Drilon, J. Clark, J. Weiss, S. Ou, D.R. Camidge, B. Solomon, G. Otterson, L. Villaruz, G. Riely, R. Heist, G. Shapiro, D. Murphy, S. Wang, T. Usari, S. Li, K. Wilner, P. Paik
Journal: Journal of Thoracic Oncology (2018)
P3.01-07 Outcome and Prognostic Factors in ALK+ve Metastatic Adenocarcinoma of Lung: Single Center Experience From Eastern India
Authors: B. Biswas, D. Dabkara, S. Ganguly, R. Shrimali, J. Ghosh, P. E, D. Midha, G. Mukherjee, M. Parihar, D. Mishra, N. Arora
Journal: Journal of Thoracic Oncology (2018)
P1.09-34 Prognostic Impact of Invasive Size, Actual Tumor Size, and Mucinous Tumor Size in Invasive Mucinous Adenocarcinoma of the Lung
Authors: T. Saito, K. Tsuta, M. Ishida, H. Matsui, Y. Taniguchi, T. Murakawa
Journal: Journal of Thoracic Oncology (2018)
P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts
Authors: J. Roeper, M. Falk, S. Schatz, M. Tiemann, S. Sackmann, D. Ukena, C. Wesseler, G. Wiest, L. Heukamp, F. Griesinger
Journal: Journal of Thoracic Oncology (2018)
Assessment of socio-economic, physical and mental health status of long-term cancer survivors
Authors: A. Gallego Martínez, B. Martínez, I. Ghanem, E. Espinosa, B. Castelo, M.P. Zamora Aunon, A. Pinto Marin, L. Ruiz-Giménez, A. Redondo, J. Feliu Batlle
Journal: Annals of Oncology (2018)
Automated survival prediction in metastatic cancer patients using high-dimensional electronic medical record data
Authors: M.F. Gensheimer, A.S. Henry, D.J. Wood, T.J. Hastie, S. Aggarwal, S. Dudley, P. Pradhan, I. Banerjee, E. Cho, K. Ramchandran, E. Pollom, A. Koong, D. Rubin, D.T. Chang
Journal: Annals of Oncology (2018)
Impact of cancer on the quality of life of Tunisian pediatric patients
Authors: F. Letaief-Ksontini, T. Dorra, S. Masmoudi, K. Meddeb, A. Mokrani, Y. Yahyaoui, A. Gabsi, M. Ayadi, N. Chraiet, H. Raies, A. Mezlini
Journal: Annals of Oncology (2018)
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate (NEPC)
Authors: L. Apostolidis, C. Nientiedt, E.C. Winkler, A.K. Berger, C. Kratochwil, A. Kaiser, D. Jäger, M. Hohenfellner, C. Hüttenbrink, S. Pahernik, F. Distler, C. Grüllich
Journal: Annals of Oncology (2018)
Abstract P061: Determinants of Incident Metabolic Syndrome and Type 2 Diabetes in Normal Weight: The Jackson Heart Study
Authors: Morgana Mongraw-Chaffin, Santiago Saldana, Mercedes R Carnethon, Haiying Chen, Valery S Effoe, Sherita H Golden, Joshua J Joseph, Rita R Kalyani, Arnita Norwood, Alain G Bertoni
Journal: Circulation (2018)

New evidence suggests that individuals with normal weight at diagnosis of type 2 diabetes (T2D) are at higher risk for all-cause mortality than those who were overweight or obese at diagnosis. While investigation of the determinants of different diabetes risk categories among those with obesity has become more common, explanations beyond genetic predisposition for the heterogeneity in risk among those without obesity are lacking. We hypothesized that visceral fat and insulin resistance would be associated with incident metabolic syndrome (MetS) and T2D among African American individuals with normal weight. In 1,032 participants of the Jackson Heart Study with normal weight (BMI 18.5 – 24.9 kg/m 2 ), we used logistic regression to investigate the determinants of incident MetS and T2D, separately. T2D and MetS were assessed at study visit 3 for the CT scan variables, and visits 2 and 3 for all other variables. We used the harmonized International Diabetes Federation criteria to define MetS. We excluded participants with prevalent MetS or T2D, and those with missing exposure or outcome data. Normal weight participants with MetS or T2D were more likely to be older, male, have lower socioeconomic status, caloric, fiber, saturated fat intake, and higher CRP and visceral fat. Higher HOMA-IR and subcutaneous fat were seen only in those with MetS. Higher visceral fat, subcutaneous fat, BMI, and HOMA-IR were significantly associated with incident MetS after adjustment for age, sex, education, and income (Figure). Only visceral fat and HOMA-IR were significantly associated with incident T2D. Estimates for BMI, but not visceral fat, were strongly attenuated with mutual adjustment. Physical activity was not associated with MetS or T2D in any model. In conclusion, visceral fat is more strongly associated with incident MetS and T2D than subcutaneous fat or physical activity, even in normal weight individuals, suggesting that adiposity plays a role in the development of cardiometabolic dysfunction even in the absence of obesity.
A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy
Authors: H. Okuyama, M. Ikeda, T. Okusaka, J. Furuse, M. Furukawa, S. Ohkawa, A. Hosokawa, Y. Kojima, K. Yamaguchi, G. Murohisa, K. Shioji, H. Ishii, N. Mizuno, M. Kojima, T. Yamanaka
Journal: Annals of Oncology (2018)
OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
Authors: A. Nowak, P. Kok, W. Lesterhuis, B. Hughes, C. Brown, S. Kao, D. Karikios, T. John, N. Pavlakis, K. O'Byrne, S. Yip, W. Lam, K. Briscoe, C. Karapetis, M. Stockler
Journal: Journal of Thoracic Oncology (2018)
P3.04-20 Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC
Authors: M. Sung, A. Zer, P. Walia, L. Khoja, M. Maganti, C. Labbe, F. Shepherd, P. Bradbury, G. Liu, N. Leighl
Journal: Journal of Thoracic Oncology (2018)
Advanced melanoma treatment patterns in the modern era: United Kingdom (UK) real world retrospective chart review study
Authors: J.J. Sacco, P.G. Corrie, O. Oladipo, M. Payne, J. Larkin, T. Talbot, J. Wagstaff, S. Cheetham, D. Stein, M. Soni, C. Coombs, A. Amadi, M. Wang, J. Ellis
Journal: Annals of Oncology (2018)
P2.15-24 Comparison of Pemetrexed Administered q 3 Weeks vs q 4 Weeks as Maintenance Therapy in NSCLC: Analysis of Real World Data from a Single Institution
Authors: G. Dy, S. Reddy, K. Wang, M. Faber, A. Meagher, H. Chen, G. Dy
Journal: Journal of Thoracic Oncology (2018)
Dynamin impacts homology-directed repair and breast cancer response to chemotherapy
Authors: Sophia B. Chernikova, Rochelle B. Nguyen, Jessica T. Truong, Stephano S. Mello, Jason H. Stafford, Michael P. Hay, Andrew Olson, David E. Solow-Cordero, Douglas J. Wood, Solomon Henry, Rie von Eyben, Lei Deng, Melanie Hayden Gephart, Asaithamby Aroumougame, Claudia Wiese, John C. Game, Balázs Győrffy, J. Martin Brown
Journal: Journal of Clinical Investigation (2018)

After the initial responsiveness of triple-negative breast cancers (TNBCs) to chemotherapy, they often recur as chemotherapy-resistant tumors, and this has been associated with upregulated homology-directed repair (HDR). Thus, inhibitors of HDR could be a useful adjunct to chemotherapy treatment of these cancers. We performed a high-throughput chemical screen for inhibitors of HDR from which we obtained a number of hits that disrupted microtubule dynamics. We postulated that high levels of the target molecules of our screen in tumors would correlate with poor chemotherapy response. We found that inhibition or knockdown of dynamin 2 (DNM2), known for its role in endocytic cell trafficking and microtubule dynamics, impaired HDR and improved response to chemotherapy of cells and of tumors in mice. In a retrospective analysis, levels of DNM2 at the time of treatment strongly predicted chemotherapy outcome for estrogen receptor–negative and especially for TNBC patients. We propose that DNM2-associated DNA repair enzyme trafficking is important for HDR efficiency and is a powerful predictor of sensitivity to breast cancer chemotherapy and an important target for therapy.
P3.01-12 EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil
Authors: E. Cronemberger, C. Baldotto, F. Marinho, P. De Marchi, L.H. Araujo, F. Franke, P. Salles, A. Calabrich, T. Almeida, M. Custodio, C. Araujo, M. Horacio, G. Castro
Journal: Journal of Thoracic Oncology (2018)
MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC
Authors: B. Halmos, A. Luft, M. Majem, R. Hui, R. Corre, M. Gümüş, K. Laktionov, B. Hermes, İ. Çiçin, A. Robinson, T. Kato, Y. Cheng, D. Kowalski, X. Li, G. Lubiniecki, B. Piperdi, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2018)
Randomized clinical trial of an individualized intervention promotes cancer patients’ prognostic awareness and reduces CPR received in the last month
Authors: C.H. Chen, J.-S. Chen, F.H. Wen, J.W.-C. Chang, W.-C. Chou, C.-H. Hsieh, M.-M. Hou, S.T. Tang
Journal: Annals of Oncology (2018)
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results
Authors: C. Hulme, P. Hall, B. Shinkins, F. Chehadah, C. McCabe, L. Hiller, J. Dunn, H.M. Earl
Journal: Annals of Oncology (2018)
P1.04-22 CD73 Immunohistochemical Expression in Malignant Cells and Correlation with Immune Infiltrate in Non-Small Cell Lung Carcinoma (NSCLC)
Authors: R. Salazar, J. Solorzano, L. Solis, C. Behrens, B. Mino, E. Parra, J. Zhang, A. Vaporciyan, D. Rice, N. Kalhor, C. Moran, D. Gibbons, A. Weissferdt, B. Sepesi, I. Wistuba
Journal: Journal of Thoracic Oncology (2018)
OP0020 Validation of new systemic lupus erythematosus classification criteria
Authors: M. Aringer, K.H. Costenbader, R. Brinks, D. Boumpas, D. Daikh, D. Jayne, D. Kamen, M. Mosca, R. Ramsey-Goldman, J.S. Smolen, D. Wofsy, B. Diamond, S. Jacobsen, W.J. McCune, G. Ruiz-Irastorza, M. Schneider, M.B. Urowitz, G. Bertsias, B. Hoyer, N. Leuchten, C. Tani, S. Tedeschi, Z. Touma, B. Anic, F. Assan, T.M. Chan, A.E. Clarke, M.K. Crow, L. Czírják, A. Doria, W. Graninger, S. Hasni, P. Izmirly, M. Jung, B. Kiss, X. Mariette, I. Padjen, J.M. Pego-Reigosa, J. Romero-Díaz, I. Rúa-Figueroa, R. Seror, G. Stummvoll, Y. Tanaka, M. Tektonidou, C. Vasconcelos, E. Vital, D.J. Wallace, S. Yavuz, R.P. Naden, T. Dörner, S.R. Johnson
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> This 4 phase project<sup>1</sup> jointly supported by EULAR and ACR has led to draft criteria.<sup>2</sup> <h3>Objectives</h3> To simplify and validate the new criteria in a large international cohort. <h3>Methods</h3> 23 expert centres each contributed up to 100 patients with SLE and with non-SLE diagnoses. Diagnoses were verified by 3 independent reviewers for 1,193 SLE and 1059 non-SLE patients. 500 randomly selected SLE and non-SLE patients formed the derivation cohort and the remainder the validation cohort. <h3>Results</h3> The criteria were fine-tuned and simplified, using ANA of ≥1:80 as entry criterion and a classification threshold of 10. Sensitivity was close to the SLICC 2012 criteria, specificity maintained at the level of the ACR 1997 criteria. This performance was independently confirmed in the validation cohort. <h3>Conclusions</h3> The new criteria developed with EULAR/ACR support achieved sensitivity close to the SLICC criteria, while maintaining the specificity of the ACR criteria. <h3>References</h3> [1] Aringer, et al. Ann Rheum Dis2017;76(S2):4. [2] Tedeschi, et al. Ann Rheum Dis2017;76(S2):50. <h3>Disclosure of Interest</h3> None declared
OA05.03 Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC
Authors: B. Creelan, J. Teer, E. Toloza, J. Mullinax, A. Landin, J. Gray, T. Tanvetyanon, M. Taddeo, D. Noyes, L. Kelley, B. Fang, J. Koomen, A. Sarnaik, S. Kim, E. Haura, S. Antonia
Journal: Journal of Thoracic Oncology (2018)
P2.01-72 Bronchial Sleeve vs Pneumonectomy: Complications, Recurrences and Survival
Authors: M. Montesinos Encalada, M. Boada, D. Sanchez, A. Libreros, A. Guirao, R. Guzman, J.M. Gimferrer, L. Molins
Journal: Journal of Thoracic Oncology (2018)
Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models
Authors: Xia Liu, Rokana Taftaf, Madoka Kawaguchi, Ya-Fang Chang, Wenjing Chen, David Entenberg, Youbin Zhang, Lorenzo Gerratana, Simo Huang, Dhwani B. Patel, Elizabeth Tsui, Valery Adorno-Cruz, Steven M. Chirieleison, Yue Cao, Allison S. Harney, Shivani Patel, Antonia Patsialou, Yang Shen, Stefanie Avril, Hannah L. Gilmore, Justin D. Lathia, Derek W. Abbott, Massimo Cristofanilli, John S. Condeelis, Huiping Liu
Journal: Cancer Discovery (2018)

Abstract Circulating tumor cells (CTC) seed cancer metastases; however, the underlying cellular and molecular mechanisms remain unclear. CTC clusters were less frequently detected but more metastatic than single CTCs of patients with triple-negative breast cancer and representative patient-derived xenograft models. Using intravital multiphoton microscopic imaging, we found that clustered tumor cells in migration and circulation resulted from aggregation of individual tumor cells rather than collective migration and cohesive shedding. Aggregated tumor cells exhibited enriched expression of the breast cancer stem cell marker CD44 and promoted tumorigenesis and polyclonal metastasis. Depletion of CD44 effectively prevented tumor cell aggregation and decreased PAK2 levels. The intercellular CD44–CD44 homophilic interactions directed multicellular aggregation, requiring its N-terminal domain, and initiated CD44–PAK2 interactions for further activation of FAK signaling. Our studies highlight that CD44+ CTC clusters, whose presence is correlated with a poor prognosis of patients with breast cancer, can serve as novel therapeutic targets of polyclonal metastasis. Significance: CTCs not only serve as important biomarkers for liquid biopsies, but also mediate devastating metastases. CD44 homophilic interactions and subsequent CD44–PAK2 interactions mediate tumor cluster aggregation. This will lead to innovative biomarker applications to predict prognosis, facilitate development of new targeting strategies to block polyclonal metastasis, and improve clinical outcomes. See related commentary by Rodrigues and Vanharanta, p. 22. This article is highlighted in the In This Issue feature, p. 1
Polygenic Determinants for Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: The St Jude Lifetime Cohort Study (SJLIFE)
Authors: Zhaoming Wang, Qi Liu, Carmen L. Wilson, John Easton, Heather Mulder, Ti-Cheng Chang, Michael C. Rusch, Michael N. Edmonson, Stephen V. Rice, Matthew J. Ehrhardt, Rebecca M. Howell, Chimene A. Kesserwan, Gang Wu, Kim E. Nichols, James R. Downing, Melissa M. Hudson, Jinghui Zhang, Yutaka Yasui, Leslie L. Robison
Journal: Clinical Cancer Research (2018)

Abstract Purpose: The risk of subsequent breast cancer among female childhood cancer survivors is markedly elevated. We aimed to determine genetic contributions to this risk, focusing on polygenic determinants implicated in breast cancer susceptibility in the general population. Experimental Design: Whole-genome sequencing (30×) was performed on survivors in the St Jude Lifetime Cohort, and germline mutations in breast cancer predisposition genes were classified for pathogenicity. A polygenic risk score (PRS) was constructed for each survivor using 170 established common risk variants. Relative rate (RR) and 95% confidence interval (95% CI) of subsequent breast cancer incidence were estimated using multivariable piecewise exponential regression. Results: The analysis included 1,133 female survivors of European ancestry (median age at last follow-up = 35.4 years; range, 8.4–67.4), of whom 47 were diagnosed with one or more subsequent breast cancers (median age at subsequent breast cancer = 40.3 years; range, 24.5–53.0). Adjusting for attained age, age at primary diagnosis, chest irradiation, doses of alkylating agents and anthracyclines, and genotype eigenvectors, RRs for survivors with PRS in the highest versus lowest quintiles were 2.7 (95% CI, 1.0–7.3), 3.0 (95% CI, 1.1–8.1), and 2.4 (95% CI, 0.1–81.1) for all survivors and survivors with and without chest irradiation, respectively. Similar associations were observed after excluding carriers of pathogenic/likely pathogenic mutations in breast cancer predisposition genes. Notably, the PRS was associated with the subsequent breast cancer rate under the age of 45 years (RR = 3.2; 95% CI, 1.2–8.3). Conclusions: Genetic profiles comprised of small-effect common variants and large-effect predisposing mutations can inform personalized breast cancer risk and surveillance/intervention in female childhood cancer survivors.
Effects of a Multimodal Program Including Simulation on Job Strain Among Nurses Working in Intensive Care Units
Authors: Radia El Khamali, Atika Mouaci, Sabine Valera, Marion Cano-Chervel, Camille Pinglis, Céline Sanz, Amel Allal, Valérie Attard, Julie Malardier, Magali Delfino, Fifina D’Anna, Pierre Rostini, Stéphan Aguilard, Karine Berthias, Béatrice Cresta, Frédéric Iride, Valérie Reynaud, Jérémie Suard, Wlady Syja, Cécile Vankiersbilck, Nicole Chevalier, Karen Inthavong, Jean-Marie Forel, Karine Baumstarck, Laurent Papazian
Journal: JAMA (2018)

Nurses working in an intensive care unit (ICU) are exposed to occupational stressors that can increase the risk of stress reactions, long-term absenteeism, and turnover.
Prognostic value of metabolic tumor volume in recurrent and/or metastatic head and neck squamous cell carcinoma treated with platinum-based chemotherapy
Authors: M. Suzuki, N. Takemoto, T. Fukuzumi, M. Yamamoto, S. Otozai, T. Yoshii, T. Fujii, H. Inohara
Journal: Annals of Oncology (2018)
The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)
Authors: E. Segelov, E. Bergsland, C. Card, T. Hope, P. Kunz, D. Laidley, B. Lawrence, S. Leyden, M. Michael, L. Modahl, S. Myrehaug, S. Padda, R. Pommier, R. Ramirez, M. Soulen, J. Strosberg, A. Thawer, B. Wei, S. Singh
Journal: Annals of Oncology (2018)
Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra)
Authors: E.A. Rozeman, K. Sikorska, L. Grijpink-Ongering, B.C. Heeres, B.A. van de Wiel, A. Sari, H. Mallo, S. Adriaansz, W. Uyterlinde, J. Lijnsvelt, L.M. Pronk, J.B.A.G. Haanen, J.W.B. de Groot, S. Wilgenhof, M.A. Vollenbergh, J.V. van Thienen, C.U. Blank
Journal: Annals of Oncology (2018)
P2.01-104 Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC is Not Correlated with TIL but has a Potential of Prognostic Value
Authors: B. Weerasubpong, C. Vinayanuwattikun, P. Chantranuwatana, V. Sriuranpong
Journal: Journal of Thoracic Oncology (2018)
A serum miRNA biomarker panel for the detection of early stage non-small cell lung cancer
Authors: L. Ying, R. Zou, L. Du, L. Shi, N. Zhang, J. Jin, J. Wu, F. Zhang, K. Chen, M. Huang, Y. Zhang, A. Lin, H. Yu, L. Zhou, W. Mao, D. Su
Journal: Annals of Oncology (2018)
P3.04-27 An Allogeneic Tumor Cell Lysate Vaccine Induces Immune Responses to Lung Cancer Associated Antigens: Preliminary Results of a Phase II Study
Authors: M. Zhang, J. Hong, T. Kunst, C. Bond, J. Yeray, M. Lee, A. Yuno, S.L. Lee, L. Xia, C. Kenney, C. Warga, T. Guerrero, T. Ripley, C. Hoang, S. Gnjatic, J. Gildersleeve, J. Trepel, D. Schrump
Journal: Journal of Thoracic Oncology (2018)
Abstract 12723: Referral to Cardiac Rehabilitation After Percutaneous Coronary Intervention, Coronary Artery Bypass Surgery, and Valve Surgery: Data From the Clinical Outcomes Assessment Program
Authors: Alexis L Beatty, Steven M Bradley, Charles Maynard, James M McCabe
Journal: Circulation (2016)

Introduction: Despite guideline recommendations that all patients undergoing percutaneous coronary intervention (PCI), coronary artery bypass surgery (CABG), or valve surgery be referred to cardiac rehabilitation, cardiac rehabilitation is underused. The objective of this study was to identify predictors of cardiac rehabilitation referral after PCI, CABG, and valve surgery. Methods: We analyzed data from the Clinical Outcomes Assessment Program (COAP), a registry of all non-federal hospitals performing PCI and cardiac surgery in Washington State. We included eligible PCI, CABG, and valve surgery patients from 2010 to 2015 who were discharged alive. We analyzed PCI and cardiac surgery separately by performing multivariate hierarchical logistic regression for the outcome of cardiac rehabilitation referral at discharge, clustered by hospital. Candidate predictors included age, gender, race/ethnicity, and comorbidities. Results: Cardiac rehabilitation referral was reported in 47% (32,049/67,556) of eligible PCI patients from 36 hospitals and 91% (19,320/21,329) of eligible cardiac surgery patients from 20 hospitals. The hospital in which the procedure was performed was a stronger multivariate predictor of referral than any individual patient characteristic for both PCI (hospital referral range 2% to 97%; median odds ratio 6.29; 95% confidence interval 4.27, 10.24) and cardiac surgery (hospital referral range 49% to 100%; median odds ratio 5.92; 95% confidence interval 3.48, 12.60)(Figure). Conclusions: Cardiac rehabilitation referral at discharge was less prevalent after PCI than cardiac surgery. The strongest predictor of cardiac rehabilitation referral was hospital in which the procedure was performed. Efforts to improve cardiac rehabilitation referral should focus on increasing referral after PCI, especially in hospitals with low referral.
Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)
Authors: R. von Moos, H. Hawle, S. Hayoz, R. Cathomas, A. Müller, S. Schmid, O. Pagani, T. Wehrhahn, D. Rauch, S. Anchisi, T. Hermanns, M. Fehr, S. Stoll, P. Bützberger, M. Zweifel, U. Huber, A.C. Fuhrer, C. Schär, S. Gillessen, A.J. Templeton
Journal: Annals of Oncology (2018)
Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
Authors: W. Abida, A.H. Bryce, N.J. Vogelzang, R.J. Amato, I. Percent, J.D. Shapiro, R. McDermott, A. Hussain, A. Patnaik, D. Petrylak, C.J. Ryan, T. Stanton, J. Zhang, A.D. Simmons, D. Despain, M. Collins, T. Golsorskhi, H.I. Scher, S. Chowdhury
Journal: Annals of Oncology (2018)